PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr PEDIAPRED®
Prednisolone Sodium Phosphate
Oral Liquid, equivalent to 5 mg / 5 mL prednisolone

H02AB06
Glucocorticoid / Anti-Inflammatory

sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval, Quebec H7V 0A3

Date of Revision:
December 21, 2020

s-a Version 8.0 dated December 21, 2020

Submission Control No: 243283
RECENT MAJOR LABEL CHANGES

Warnings and Precautions, May 2020
Contraindications, May 2020
Adverse Reactions, Post-Market Adverse Reactions, May 2020
Drug Interactions, Drug-Drug Interactions, May 2020
Warnings and Precautions, Endocrine and Metabolism, December 2020
Adverse Reactions, Post-Market Adverse Reactions, December 2020

TABLE OF CONTENTS

TABLE OF CONTENTS ..............................................................................................................2

PART I: HEALTH PROFESSIONAL INFORMATION .................................................................4

1 INDICATIONS ....................................................................................................................4
1.1 Pediatrics ....................................................................................................................4

2 CONTRAINDICATIONS ....................................................................................................4

3 DOSAGE AND ADMINISTRATION ....................................................................................4
3.1 Dosing Considerations ...............................................................................................4
3.2 Recommended Dose and Dosage Adjustment ...........................................................4
3.3 Administration ...........................................................................................................5
3.4 Missed Dose ...............................................................................................................5

4 OVERDOSAGE .................................................................................................................6

5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .........................6

6 WARNINGS AND PRECAUTIONS ..................................................................................6
6.1 Special Populations ..................................................................................................11
6.1.1 Pregnant Women .................................................................................................11
6.1.2 Breast-feeding .....................................................................................................11
6.1.3 Pediatrics .............................................................................................................11
6.1.4 Geriatrics .............................................................................................................11

7 ADVERSE REACTIONS ....................................................................................................12
7.1 Adverse Reaction Overview ....................................................................................12
7.2 Clinical Trial Adverse Reactions .............................................................................12
7.3 Post-Market Adverse Reactions ...............................................................................13

8 DRUG INTERACTIONS ...................................................................................................14
8.1 Overview ..................................................................................................................14
8.2 Drug-Drug Interactions ............................................................................................14
8.3 Drug-Laboratory Test Interactions ..........................................................................17

9 ACTION AND CLINICAL PHARMACOLOGY ...............................................................17
9.1 Mechanism of Action ...............................................................................................17
9.2 Pharmacodynamics .................................................................................................18
9.3 Pharmacokinetics .....................................................................................................19

10 STORAGE, STABILITY AND DISPOSAL ....................................................................20
PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Management of conditions known to be responsive to PREDNISONE or PREDNISOLONE where anti-inflammatory action or immunosuppression or adrenocortical supplementation and replacement is required.

For most indications, glucocorticoid administration provides symptomatic relief, but has no effect on the underlying disease processes. Use of these medications does not eliminate the need for other therapies that may be required.

1.1 Pediatrics

PEDIAPRED is appropriate for pediatric usage and for those patients with difficulty swallowing solid oral dosage forms.

2 CONTRAINDICATIONS

PEDIAPRED is contraindicated in patients with:
- Untreated systemic fungal infections.
- Known hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition and Packaging.
- Any infectious condition (including measles, or uncontrolled active infections).
- Some progressive herpes group viruses (including hepatitis, herpes, varicella, shingles).
- Psychotic states still not controlled by a treatment.
- Live vaccines (when PEDIAPRED is used at immunosuppressive doses).

3 DOSAGE AND ADMINISTRATION

3.1 Dosing Considerations

Standardized dosing is not available for oral corticosteroids. Therefore, any adjustments in consideration of age or renal function of the patient should be taken into account, along with the patient's weight and severity of the disease when the initial dosage is established.

3.2 Recommended Dose and Dosage Adjustment

The initial dosage may vary from 5 to 60 mg prednisolone base per day, depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice, while in selected patients, higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, PEDIAPRED should be discontinued, and the patient transferred to other appropriate therapy.
IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements, at appropriate time intervals, until the lowest dosage, which will maintain an adequate clinical response, is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage.

Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation, it may be necessary to increase the dosage of prednisolone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly, to avoid glucocorticoid withdrawal syndrome.

<table>
<thead>
<tr>
<th>NAME</th>
<th>MG/DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisone</td>
<td>25</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>20</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>5</td>
</tr>
<tr>
<td>Prednisone</td>
<td>5</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>4</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>4</td>
</tr>
<tr>
<td>Paramethasone</td>
<td>2</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.6</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>0.75</td>
</tr>
</tbody>
</table>

1. These dose relationships apply only to oral or intravenous administration of these compounds.
2. When these substances or their derivatives are injected intra-muscularly into joint spaces, their relative properties may be greatly altered.

3.3 Administration

If on a once-daily therapy, PEDIAPRED should be administered in the morning to simulate the natural circadian rhythm of corticosteroid secretion.

3.4 Missed Dose

The course of action will depend on the dosage regimen:

One dose every other day: The missed dose should be taken as soon as possible the same morning, and the regular dosing schedule should be resumed. If it is later in the day, the missed dose should be taken the next morning, and the regular dosing schedule should be resumed after skipping a day.
One dose a day: The missed dose should be taken as soon as possible, and the regular dosing schedule should be resumed. If the patient has missed a day, the missed dose should be skipped, and the regular dosing schedule should be resumed. The patient should be advised not to take a double dose to compensate for the missed one.

Several doses a day: The missed dose should be taken as soon as possible, and the regular dosing schedule should be resumed. If it is time for the next dose, the dose should be doubled, and the regular dosing schedule should be resumed.

4 OVERDOSAGE

The effects of accidental ingestion of large quantities of prednisolone over a very short period of time have not been reported.

Treatment of acute overdosage is by immediate gastric lavage or emesis. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of prednisolone may be reduced only temporarily, or alternate day treatment may be introduced.

For management of a suspected drug overdose, contact your regional poison control centre.

5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging.

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength/Composition</th>
<th>Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Liquid, 5 mg / 5 mL prednisolone</td>
<td>Artificial raspberry flavor, dibasic sodium phosphate, edetate disodium, methylparaben, purified water, sodium phosphate monobasic, sorbitol.</td>
</tr>
</tbody>
</table>

PEDIAPRED is a dye-free, colourless to, slightly yellow raspberry-flavored solution supplied in 120 mL bottles. Each 5 mL (teaspoonful) contains 5.0 mg prednisolone base (as prednisolone sodium phosphate) in a palatable, aqueous vehicle.

6 WARNINGS AND PRECAUTIONS

General

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment, and as to whether daily or intermittent therapy should be used.

Patients should be warned not to discontinue the use of PEDIAPRED abruptly or without medical supervision, to advise any medical attendants that they are taking PEDIAPRED and to seek medical advice at once should they develop fever or other signs of infection.
Corticosteroids should be used with caution in the following clinical conditions: non-specific ulcerative colitis (if there is a probability of impending perforation), abscess or other pyogenic infection, diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, cardiac disease, thromboembolic disorders and diabetes mellitus.

Carcinogenesis and Mutagenesis

Limited information is available. Glucocorticoids produce cleft palate in the offspring when administered to pregnant mice, rats and hamsters. There are few studies on the carcinogenicity or mutagenicity of prednisolone in animals.

Cardiovascular

Literature reports suggest an association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with caution in these patients.

Driving and Operating Machinery

PEDIAPRED may cause blurred vision, which may affect one’s ability to drive (see ADVERSE REACTIONS). Due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery.

Endocrine and Metabolism

Electrolytes
Average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

Hypothyroidism
There is an enhanced effect of corticosteroids in patients with hypothyroidism.

Pheochromocytoma Crisis
Pheochromocytoma crisis, which can be fatal, has been reported after administration of corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

Secondary Adrenocortical Insufficiency
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstated. Since mineralocorticoid secretion may be impaired, salt and/or mineralocorticoid should be administered concurrently.

Suppression of HPA (Hypothalamic-Pituitary-Adrenal) Function
Glucocorticoid-induced suppression of HPA function is dependent on dose and duration of treatment. Recovery occurs gradually as the steroid dose is reduced and withdrawn. Suppression persists for a period of time after withdrawal depending on dose and length of
treatment time. In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated.

Tumor Lysis Syndrome
In post marketing experience, tumor lysis syndrome (TLS) has been reported in patients with hematological malignancies following the use of PEDIAPRED alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with high proliferative rate, high tumor burden, and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken (see ADVERSE REACTIONS).

Gastrointestinal
In the case of a history of ulcers, corticotherapy may be prescribed, with clinical monitoring and after endoscopy when needed.

Hematologic
Aspirin (ASA) and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Hepatic/Biliary/Pancreatic
There is an enhanced effect of corticosteroids in patients with cirrhosis of the liver.

Corticosteroid use requires monitoring that is specifically adapted in patients with hepatic failure.

Immune
Infections
Unless they have had varicella or measles, patients should avoid contact with subjects who have varicella, herpes zoster and measles. If they are exposed to such infections whilst receiving PEDIAPRED, they must contact a physician immediately even if there are no symptoms.

Patients who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Immunosuppressed patients should be warned to avoid exposure to varicella or measles. Varicella and measles can have a more serious or even fatal course in non-immune children or adults who have not had these diseases, and particular care should be taken to avoid exposure. It is not known whether the risk of developing serious cases of these infections is due to prior corticosteroid treatment, or to the contribution of the underlying disease which is being treated. If exposed to varicella, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. If varicella develops, treatment with antiviral agents may be considered.

The use of PEDIAPRED is contraindicated in patients with varicella, measles or uncontrolled active infections (see CONTRAINDICATIONS).

While on corticosteroid therapy, patients should not be vaccinated with any live vaccine (see CONTRAINDICATIONS). Other immunization procedures should not be undertaken in
patients who are on corticosteroids, especially on high doses, because of possible hazards of neurological complications and lack of antibody response.

Other people living with the patient should not receive oral polio vaccine, due to risk of passing on the polio virus.

Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used.

If corticosteroids have to be used in the presence of fungal or bacterial infections, institute appropriate anti-infective therapy and closely monitor.

In the case of known or suspected Strongyloides (threadworm) infestation, immunosuppression may lead to hyperinfection and dissemination, leading to severe enterocolitis and potentially fatal gram-negative septicemia (oral).

The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy these patients should receive chemoprophylaxis.

**Monitoring and Laboratory Tests**

During prolonged corticosteroid therapy, routine laboratory studies such as urinalysis, 2-hour postprandial blood sugar determinations, blood pressure monitoring, body weight and chest X-ray should be performed at regular intervals. If doses of prednisolone are high, serum potassium should be monitored regularly. Serious consideration of upper gastrointestinal studies should be contemplated when patients complain of gastric symptoms while on this medication. In general, prolonged therapy above 8 mg/day is associated with increased incidence of adverse effects; mental disorders are associated with doses exceeding 40 mg/day.

**Musculoskeletal**

Myasthenia Gravis
In myasthenia gravis, hospitalization with careful observation is recommended because transient worsening of symptoms, possibly leading to respiratory distress, may precede clinical improvement.

Tendinopathy
Oral or injectable corticosteroids may promote the onset of tendinopathy, even tendon rupture (rare). This risk is increased during the co-prescription with fluoroquinolones and in dialysis patients with secondary hyperparathyroidism or who have undergone a kidney, heart or lung transplant, and in patients older than 60 years of age.

**Ophthalmologic**
Visual disturbance may be associated with systemic and topical corticosteroid use. Prolonged use of corticosteroids may produce posterior subcapsular cataracts or glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi or viruses.

**Chorioretinopathy**
Systemic glucocorticoid treatment can cause chorioretinopathy which can lead to visual disorders including visual loss. Prolonged use of systemic glucocorticoid treatment even at low dose can cause chorioretinopathy. If a patient under glucocorticoid treatment presents with blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes (which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR)).

**Ocular Herpes Simplex**
Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

**Psychiatric**

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

**Dependence/Tolerance**
Following prolonged therapy, psychological and/or physiological dependence may develop (see ADVERSE REACTIONS). Withdrawal of glucocorticoids may result in symptoms of the glucocorticoid withdrawal syndrome including: fever, myalgia, arthralgia and malaise. This may occur in patients even without evidence of adrenal insufficiency.

**Renal**

In patients with systemic sclerosis, cases of scleroderma renal crisis (including fatal cases) with hypertension and/or decreased urinary output have been reported with a daily dose of 15 mg or more of prednisolone. Blood pressure and renal function (serum creatinine) should therefore be routinely checked in such patients (see ADVERSE REACTIONS).

**Sexual Health**

**Reproduction**
Steroids may increase or decrease motility and number of spermatozoa in some male patients. However, it is not known whether reproductive capacity in humans is adversely affected.

**Skin**

Cases of acne, ecchymosis, contusion, skin atrophy, hypertrichosis, purpura, skin discoloration, and striae have been reported with PEDIAPRED use (see ADVERSE REACTIONS, Post-Market Adverse Reactions).
6.1 Special Populations

6.1.1 Pregnant Women

Prednisolone sodium phosphate (corticosteroids) has been shown to be teratogenic in various animal species when given in doses equivalent to the human dose. There are no adequate and well controlled studies in pregnant women. PEDIAPRED should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies in which prednisolone sodium phosphate has been given to pregnant rodents and rabbits have yielded an increased incidence of cleft palate in the offspring.

Infants born to mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

During chronic diseases requiring treatment throughout pregnancy, an intrauterine growth retardation is possible.

It is justified to monitor the newborn baby clinically (weight, diuresis) and biologically for a while.

6.1.2 Breast-feeding

Prednisolone sodium phosphate is excreted in breast milk. Caution should be exercised when PEDIAPRED is administered to a nursing woman.

In the case of a chronic treatment at high doses, breastfeeding is not recommended.

6.1.3 Pediatrics

Hypertrophic cardiomyopathy has been reported after systemic administration of glucocorticosteroids in preterm infants. In infants receiving administration of systemic glucocorticosteroids, echocardiograms should be performed to monitor myocardial structure and function.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Administration of corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.

Pediatric patients demonstrate greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients. HPA axis suppression, Cushing's syndrome and intracranial hypertension have been reported in children taking oral corticosteroids. This is commonly related either to the withdrawal or reduction in dose of a steroid, or to a change in another drug. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema.

6.1.4 Geriatrics

Clearance of prednisolone is impaired in geriatric patients. Corticosteroid use requires monitoring that is specifically adapted in elderly subjects.
Cases of acne, ecchymosis, contusion, skin atrophy, hypertrichosis, purpura, skin discoloration, and striae have been reported with PEDIAPRED use (see ADVERSE REACTIONS, Post-Market Adverse Reactions).

7 ADVERSE REACTIONS

7.1 Adverse Reaction Overview

Corticosteroids have a potential for multiple adverse effects. There are essentially two types of toxicity observed when administered in therapeutic dosages: withdrawal effects, which could produce life-threatening adrenal insufficiency, and high dosage over long periods, which could produce fluid/electrolyte disturbances, hyperglycemia, increased susceptibility to infections, peptic ulceration, osteoporosis, myopathy, behavioural disturbances, cataracts, or Cushing’s habitus. Single doses, or short courses of therapy (over several days), are usually associated with less harmful effects. The approach to therapy should follow logical and rational sequence of: (i) attempting to control the condition with more conventional mode(s) of management, (ii) weighing the benefits of steroid therapy against the risks, (iii) commencing therapy with high loading dose, reducing to the minimum effective dosage as soon as possible.

7.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Cardiac Disorders
Congestive heart failure in susceptible patients. Hypertrophic cardiomyopathy in preterm infants.

Endocrine Disorders
Menstrual irregularities, development of iatrogenic cushingoid syndrome, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, suppression or retardation of growth in children, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics, pheochromocytoma crisis.

Fluid and Electrolyte Disturbances
Sodium retention, fluid retention, potassium loss, hypokalemic alkalosis.

Gastrointestinal Disorders
Peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, ulcerative esophagitis.

Metabolism and Nutrition Disorders
Negative nitrogen balance due to protein catabolism.

Musculoskeletal and Connective Tissue Disorders
Muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones.

Nervous System Disorders
Convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment withdrawal, vertigo, headache.

**Ophthalmic Disorders**
Posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos, blurred vision, chorioretinopathy.

**Renal and Urinary Disorders**
Scleroderma renal crisis*

*Amongst the different subpopulations the prevalence of scleroderma renal crisis varies. The highest risk has been reported in patients with diffuse systemic sclerosis. The lowest risk has been reported in patients with limited systemic sclerosis and juvenile onset systemic sclerosis.

**Skin and Subcutaneous Tissue Disorders**
Impaired wound healing, thin fragile skin, petechiae, ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests.

**Vascular Disorders**
Hypertension.

7.3 Post-Market Adverse Reactions

**Endocrine Disorders**
Adrenal suppression, adrenocortical atrophy.

**Gastrointestinal Disorders**
Small intestine ulceration.

**Immune System Disorders**
Hypersensitivity reactions.

**Metabolism and Nutrition Disorders**
Hypokalemia, metabolic alkalosis. Cases of tumor lysis syndrome have been reported in association with PEDIAPRED when used in patients with hematological malignancies (see WARNINGS AND PRECAUTIONS).

**Musculoskeletal and Connective Tissue Disorders**
Muscle atrophy preceded by muscle weakness (increased protein catabolism), tendon rupture.

**Nervous System Disorders**
Seizures.

**Psychiatric Disorders:**
Insomnia, euphoria, depressed state when treatment is discontinued, restlessness, manic-like episodes, delirium or confused dream-like states.

**Skin and Subcutaneous Tissue Disorders**
Acne, contusion, skin atrophy, hypertrichosis, purpura, striae.
8 DRUG INTERACTIONS

8.1 Overview

Since prednisolone sodium phosphate is metabolized in the liver, the possibility exists that concomitant administration of other hepatically metabolized drugs may lead to interactions (e.g. barbiturates). Dosage adjustment may be required for hepatic CYP450 enzyme inducers and inhibitors.

It is recommended to increase the maintenance dose of glucocorticoids if the following drugs are administered at the same time: anticonvulsants (phenobarbital, phenytoin), certain antibiotics (rifampin), anticoagulants (coumarin) and bronchodilators (ephedrine). If the patient receiving glucocorticoids is treated at the same time with some other antibiotics (erythromycin), ketoconazole, estrogens or preparations containing estrogens, a reduction in the dose of prednisolone sodium phosphate is recommended.

8.2 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 2 – Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Proper/Common name</th>
<th>Source of Evidence</th>
<th>Effect</th>
<th>Clinical comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>T</td>
<td>↑ effect</td>
<td>Alcohol and prednisolone can each irritate the digestive tract. The effect can be potentiated by taking the two concurrently.</td>
</tr>
<tr>
<td>Antacids</td>
<td>T</td>
<td>↓ absorption</td>
<td>Antacids can decrease the absorption of prednisolone.</td>
</tr>
<tr>
<td>Anticholinesterases</td>
<td>T</td>
<td>↓ efficacy</td>
<td>Anticholinesterase effects may be antagonized in myasthenia gravis.</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>T</td>
<td>↑ efficacy</td>
<td>The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.</td>
</tr>
<tr>
<td>(e.g. coumarin)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporin</td>
<td>T</td>
<td>↑ toxicity</td>
<td>Toxicity may be enhanced when cyclosporin and glucocorticoids are combined in organ transplant patients.</td>
</tr>
<tr>
<td>Proper/Common name</td>
<td>Source of Evidence</td>
<td>Effect</td>
<td>Clinical comment</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------</td>
<td>--------</td>
<td>-----------------</td>
</tr>
<tr>
<td>CYP3A inhibitors (e.g. cobicistat-containing products)</td>
<td>T</td>
<td>↑ risk of systemic corticosteroid effects</td>
<td>Co-treatment with CYP3A inhibitors, including cobicistat-containing products, may increase the risk of systemic corticosteroid side-effects. The combination should be avoided unless the benefit outweighs the increased risk of such side-effects, in which case patients should be closely monitored.</td>
</tr>
</tbody>
</table>
| Digitalis glycosides (e.g. digoxin) | T | ↑ toxicity | Co-administration with digitalis glycosides may enhance the possibility of digitalis toxicity associated with hypokalemia.  
Digoxin should be used in combination with caution because hypokalemia favors the toxic effects of cardiac glycosides. Correct any hypokalemia beforehand and carry out clinical, electrolyte, and electrocardiographic monitoring. |
| Enzyme-inducing anticonvulsants | T | ↓ plasma concentration and efficacy | Enzyme-inducing anticonvulsants should be used in combination with caution. There is risk of decreased plasma concentrations and efficacy of corticosteroids due to an increase in their hepatic metabolism by the inducer.  
The consequences are particularly significant in patients with Addison’s disease treated with hydrocortisone and in the case of transplantation. Clinical and biological monitoring are recommended, as well as adjustment of the dosage of corticosteroids during treatment through the inducer and after its discontinuation. |
<p>| Fluoroquinolones | T | ↑ risk of tendinopathy | There is a possible increased risk of tendinopathy, even tendon rupture (rare), particularly in patients receiving prolonged corticotherapy. |</p>
<table>
<thead>
<tr>
<th>Proper/Common name</th>
<th>Source of Evidence</th>
<th>Effect</th>
<th>Clinical comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypokalemia-inducing drugs</td>
<td>T</td>
<td>↑ risk of hypokalemia and cardiac rhythm disturbances</td>
<td>Hypokalemia-inducing medicinal products (hypokalemia-inducing diuretics alone or combined, stimulant laxatives, amphotericin B by IV route, tetracosactide) should be used in combination with caution due to the increased risk of hypokalemia. Monitoring of serum potassium with, if needed, correction. Hypokalemia is a factor favouring the onset of cardiac rhythm disturbances (particularly torsades de pointes) and increasing the toxicity of some medicinal products. Therefore, the medicinal products that may cause hypokalemia are involved in a large number of interactions.</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>T</td>
<td>↓ plasma concentration</td>
<td>Isoniazid should be used in combination with caution. There is risk of decreased plasma concentrations of isoniazid by increasing acetylation rate and/or renal clearance which may reduce isoniazid efficacy. Clinical and biological monitoring are recommended.</td>
</tr>
<tr>
<td>Medicines containing potassium and sodium</td>
<td>T</td>
<td>↑ absorption of sodium and water</td>
<td>Glucocorticoids increase sodium and water absorption and potassium secretion. Monitoring is recommended.</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>T</td>
<td>↑ risk of ulceration and hemorrhage</td>
<td>Co-administration with NSAIDs may increase the risk of gastrointestinal ulceration and gastrointestinal hemorrhage.</td>
</tr>
<tr>
<td>Potassium-depleting agents</td>
<td>T</td>
<td>↑ hypocalcemia and hypokalemia</td>
<td>Potassium-depleting agents (e.g. thiazide diuretics) may enhance hypocalcemia and hypokalemia secondary to glucocorticoid use.</td>
</tr>
<tr>
<td>Salicylates</td>
<td>T</td>
<td>↓ plasma concentration</td>
<td>Salicylate serum concentrations may be decreased upon co-administration with glucocorticoids.</td>
</tr>
</tbody>
</table>
### 8.3 Drug-Laboratory Test Interactions

Glucocorticoids may alter laboratory or radiological tests for serum T₃ or serum protein-bound iodine, may decrease T₄ minimally or decrease the uptake of ¹³¹I iodine.

### 9 ACTION AND CLINICAL PHARMACOLOGY

#### 9.1 Mechanism of Action

PEDIAPRED is a synthetic adrenocortical steroid derivative with predominantly glucocorticoid properties possessing anti-inflammatory and immunosuppressive action.

Prednisolone sodium phosphate belongs to the pharmacologic class of glucocorticoid / anti-inflammatory drugs which, following systemic absorption, diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes may enter the cell nucleus, bind to DNA and stimulate transcription of mRNA. Subsequent cellular responses result in a variety
of local and systemic effects. Inflammatory processes such as edema, fibrin deposition, decreased prostaglandin/thromboxane synthesis, capillary dilatation, migration of leukocytes, the phagocytosis stage of wound healing and cicatrization are inhibited. Immune reactions are suppressed. Metabolically, protein catabolism and increased gluconeogenesis, along with decreased peripheral utilization of glucose, leads to glycogen storage in the liver, increased blood glucose concentration and insulin resistance (diabetogenic effect). During therapy lipolysis is enhanced and abnormal distribution of fat may result (Cushingoid effect). Skeletal calcium is mobilized and lost via renal excretion. Glucocorticoids, in general, augment renal glomerular filtration and promote urate excretion.

In respect of electrolyte and water balance, sodium tends to be reabsorbed and potassium and hydrogen excreted resulting in water retention and risk of hypokalemic alkalosis.

Prednisolone is rapidly and well absorbed from the gastrointestinal tract following oral administration. PEDIAPRED Oral Liquid produces a 20% higher peak plasma level of prednisolone which occurs approximately 15 minutes earlier than that seen with tablet formulations. Prednisolone is 70-90% protein-bound in the plasma and it is eliminated from the plasma with a half-life of 2 to 4 hours. It is metabolized mainly in the liver and excreted in the urine as sulphate and glucuronide conjugates.

9.2 Pharmacodynamics

Prednisolone sodium phosphate is a synthetic corticosteroid with, primarily, glucocorticoid activity. Its primary actions are via control of protein synthesis, eliciting specific effects within given metabolic systems. Corticosteroids generally act by (i) conversion of protein to carbohydrate, protecting glucose-dependent cerebral functions by stimulating glucose formation; (ii) decreasing glucose utilization in peripheral tissue and increasing hepatic glucogen storage; (iii) promoting gluconeogenesis by peripheral and hepatic activity, protein catabolism for amino acid mobilization as substrate for glucose/glycogen production.

Glucocorticoids have only slight mineralocorticoid activity; however, prednisolone can promote sodium influx and potassium efflux across cell membranes and decreases calcium absorption by the gastrointestinal tract. Although not thought to be related to electrolyte imbalance, prednisolone, during prolonged therapy, may result in hypertension due to unclear etiology. Decreased bone formation, and increased resorption do occur as a result of decreased calcium absorption which decreases plasma calcium levels, increasing PTH secretion and osteoclast activity.

Excessive amounts of glucocorticoids such as prednisolone causes skeletal muscle wasting. The mechanism for this is not known.

The effects on the Central Nervous System are varied - mood elevation, euphoria, insomnia; this may be due to an increase in brain excitability unrelated to sodium or potassium levels.

Glucocorticoids increase the hemoglobin and red cell content of blood, and retard erythrophagocytosis. They increase the number of polymorphonuclear leukocytes, decrease lymphocytes, eosinophils and monocytes. T-lymphocytes are depressed more than β-lymphocytes.

Glucocorticoids prevent or suppress tissue response to the inflammatory process and reduce the symptoms of inflammation without affecting the underlying cause. Their action is via the
inhibition of neutrophil, leukocyte, monocyte-macrophage accumulation at the site of inflammation. Glucocorticoids are effective in the prevention and suppression of cell-mediated (delayed hypersensitivity) immune reactions which may occur via similar mechanisms, as described for anti-inflammatory activity.

For prednisolone, as other glucocorticoids, usage and dosage varies depending on the indication, the duration of treatment, and the reaction of the patient. In general, high doses are administered for short term therapy, and the lowest possible dose which provides adequate response is maintained for long term therapy. The daily dosage can range from 5 - 100 mg prednisolone.

Prednisolone is an extremely potent and effective agent, with the potential for multiple adverse effects. There are essentially 2 types of toxicity observed when administered in therapeutic dosages: withdrawal effects, which could produce life-threatening adrenal insufficiency; and high dosage over long periods, which could produce fluid/electrolyte disturbances, hyperglycemia, increased susceptibility to infections, peptic ulceration, osteoporosis, myopathy, behavioural disturbances, cataracts, or Cushings’ habitus. Single doses, or short courses of therapy (over several days) are usually without harmful effects. The approach to institution of therapy should follow the sequence of: (i) attempting to control the condition with more conventional mode(s) of therapy; (ii) weighing the benefits of steroid therapy against the risks; (iii) commencing therapy with a high loading dose, reducing to the minimum effective dosage as soon as possible.

During prolonged therapy, routine laboratory studies such as urinalysis, 2-hour postprandial blood sugar determinations, body weight and chest X-ray should be performed at regular intervals. If doses of prednisolone are high, serum potassium should be monitored regularly. If the patient has a history of gastrointestinal (GI) disturbances, upper GI X-rays should be performed. Prolonged therapy above 8 mg/day is associated with increase rise of adverse effects; mental disorders are associated with doses exceeding 40 mg/day.

9.3 Pharmacokinetics

Absorption:
Prednisolone is rapidly and almost completely absorbed following oral administration. It is reversibly bound (90%) with high affinity to corticosteroid binding globulin (Transcortin) or to albumin, with lower affinity, in plasma. Caution should be exercised in patients with decreased serum protein binding of steroids, as the free, or pharmacologically active, prednisolone levels can vary. Prednisolone is the active form; it is also the active metabolite of prednisone, which must be converted to prednisolone for biological activity. The pharmacokinetics of prednisolone are as follows:

<table>
<thead>
<tr>
<th>% Availability (oral)</th>
<th>82 +/- 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Urinary Excretion</td>
<td>90 - 95</td>
</tr>
<tr>
<td>Clearance (mL.min^-1.kg^-1)</td>
<td>8.7 +/- 1.6</td>
</tr>
<tr>
<td>Volume of Dist. (L/kg)</td>
<td>1.5 +/- 0.2</td>
</tr>
<tr>
<td>T_1/2 (hours)</td>
<td>2.2 +/- 0.1</td>
</tr>
</tbody>
</table>

Metabolism:
Prednisolone is metabolized primarily by the liver and excretion is mainly renal.
10 STORAGE, STABILITY AND DISPOSAL

Store at 15-30°C. Do not refrigerate. Keep bottle tightly closed.

Keep out of reach and sight of children.
PART II: SCIENTIFIC INFORMATION

11 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Prednisolone sodium phosphate

Chemical name: 11, 17-dihydroxy-21-phosphonooxy)-disodium salt, (11β)-pregna-1, 4 diene-3, 20-dione

Molecular formula: C_{21}H_{27}Na_{2}O_{8}P

Molecular mass: 484.39

Structural formula:

Physicochemical properties: White or slightly yellow friable granules or powder, freely soluble in water, soluble in methanol, slightly soluble in alcohol and chloroform, very slightly soluble in acetone and in dioxane.

12 NON-CLINICAL TOXICOLOGY

Limited information is available. Glucocorticoids produce cleft palate when administered to pregnant mice, rats and hamsters. There are few studies on the carcinogenicity or mutagenicity of prednisolone in animals.
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

PEDIAPRED
Oral Liquid, equivalent to 5 mg / 5 mL prednisolone

Read this carefully before you start taking PEDIAPRED and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about PEDIAPRED.

What is PEDIAPRED used for?
PEDIAPRED is used to:
• help replace the corticosteroids normally produced by your body, or
• provide relief from inflammation or allergies from many diseases.

It may be given to you as part of a treatment for a problem you may have.

How does PEDIAPRED work?
PEDIAPRED works by lowering the activity of your immune system. PEDIAPRED will slow your body’s response to a disease or injury.

What are the ingredients in PEDIAPRED?
Medicinal ingredient: Prednisolone sodium phosphate
Non-medicinal ingredients: Artificial raspberry flavor, dibasic sodium phosphate, edetate disodium, methylparaben, purified water, sodium phosphate monobasic, sorbitol.

PEDIAPRED comes in the following dosage forms:
Oral liquid, 5 mg / 5 mL

Do not use PEDIAPRED if:
• you have an untreated systemic fungal infection.
• you are allergic to any ingredients in this drug or the container.
• you have an infection or herpes virus such as chicken pox, measles, hepatitis, herpes, or shingles.
• you experience psychotic episodes that are not controlled by a treatment.
• you have recently received a live vaccine, such as a vaccine for measles, mumps, rubella, or chicken pox.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PEDIAPRED. Talk about any health conditions or problems you may have, including if you have:
• AIDS or other infections.
• stomach or intestine problems.
• bone disease.
• high blood sugar (diabetes).
• heart disease or had a heart attack.
• high or low blood pressure.
• kidney disease or stones.
• liver problems like cirrhosis.
• parasites called threadworms.
• lung disease.
• muscle pain or weakness.
• tendon problems.
• skin problems.
• above normal hair growth.
• eye problems such as glaucoma, cataracts, herpes infection, or any problems with the retina.
• have disorders that affect glands and hormones (endocrine system) like:
  – low potassium or calcium.
  – thyroid problems (hypothyroidism).
  – high levels of stress that are not normal.
  – tumors in your adrenal glands.
• certain mental or mood conditions (such as depression, trouble sleeping, mood swings).

Other warnings you should know about:
• If you have scleroderma (systemic sclerosis), a disease that hardens and tightens skin, daily doses of 15 mg or more of PEDIAPRED may increase the risk of scleroderma renal crisis. This can cause blood pressure to rise and less urine to be made.
• If you have never had chicken pox or measles, you should avoid contact with people with chicken pox, shingles and measles.
  – If you were in contact with these infections, tell your healthcare professional right away, even if there are no symptoms.
• Do not get any vaccines while taking PEDIAPRED.
• Other people living in your home should not get the oral polio vaccine. There is a chance they could pass the polio virus on to you.
• PEDIAPRED might affect skin test results.

Tumor Lysis Syndrome
• PEDIAPRED may cause Tumor Lysis Syndrome. This is a problem where large amounts of cancer cells are killed quickly by the cancer treatment. The contents of the dead cancer cells are then released into your blood. Speak to your healthcare professional if you have a cancer that affects your blood. Your healthcare professional should monitor you closely if you have high levels of uric acid in your blood.

Male Patients
• PEDIAPRED may affect sperm count and how they work in some men. It is not known if this will affect your ability to father a child.

Female Patients
• Talk to your healthcare professional if you are pregnant, or trying to become pregnant, or are breastfeeding or intend to breastfeed.
• Your healthcare professional will talk to you about the possible serious risks of PEDIAPRED to your unborn baby if you become pregnant.

Pediatric Patients
• A child’s heart might get thicker than normal while taking PEDIAPRED.
• Children are at higher risk to get disorders that affect glands and hormones, like Cushing’s Syndrome, while taking PEDIAPRED.
• PEDIAPRED can affect growth in children.

Geriatric Patients
• Problems of removing PEDIAPRED from the body can happen in geriatrics.

Driving and Using Machines: PEDIAPRED can cause blurred vision. Before you do tasks which may require attention, wait until you know how you respond to PEDIAPRED.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with PEDIAPRED:
• Anticholinesterases, drugs that treat skeletal muscle weakness.
• Coumarin, used to thin the blood.
• Ephedrine, used to prevent low blood pressure.
• Cyclosporin, used to prevent organ transplant rejection.
• CYP3A inhibitors (cobicistat-containing products).
• Digitalis glycosides like digoxin, used to treat heart problems or high blood pressure.
• Anticonvulsants like phenobarbital, phenytoin and carbamazepine, used to treat epilepsy and seizures.
• Rifampin, erythromycin, and fluoroquinolones, antibiotics used to treat infections.
• Diuretics, laxatives, amphotericin B, and tetracosactide, drugs that cause low potassium levels.
• Isoniazid, an antibiotic used to treat tuberculosis.
• Ibuprofen and acetysalicylic acid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Potassium-depleting agents (e.g. thiazide diuretics).
• Vaccines.
• Salicylates, such as aspirin, used to treat fever, pain, and swelling.
• Antacids, such as calcium carbonate, magnesium hydroxide, or aluminum hydroxide, used to treat stomach upset and heart burn.
• Medicines used to treat diabetes.
• Drugs containing potassium or sodium.
• Alcohol. Stomach problems may happen if you drink alcoholic drinks while being treated with PEDIAPRED.

How to take PEDIAPRED:
• Take PEDIAPRED with food to help prevent an upset stomach.
• Do not give PEDIAPRED to other people.
• Your healthcare professional will monitor your health. They may interrupt, reduce, or stop your dose. This may occur based on your current health, if you take certain other medications or if you have certain side effects.

Recommended dose:
• Take PEDIAPRED as directed by your healthcare professional.
• Do not take more or less than the recommended dose prescribed by your healthcare professional.
• Do not change the dose or schedule unless your healthcare professional tells you to.
• Do not stop taking PEDIAPRED unless your healthcare professional tells you to.

**Overdose:**

If you think you have taken too much PEDIAPRED, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

**Missed Dose:**

If a dose of PEDIAPRED is missed and your dosing schedule is:

One dose every other day:
- Take the missed dose as soon as possible if you remember it the same morning. Take the next dose at your regular time.
- If you do not remember the missed dose until later in the day, wait and take it the next morning. Then skip a day and take your next dose at your regular time.

One dose a day:
- Take the missed dose as soon as possible, then take your next dose at your regular time.
- If you do not remember until the next day, skip the missed dose and take your next dose at your regular time. Do not double the dose to make up for a missed dose.

Several doses a day:
- Take the missed dose as soon as possible, then take your next dose at your regular time.
- If you do not remember until your next dose is due, double that dose, then take your next dose at your regular time.

**What are possible side effects from using PEDIAPRED?**

These are not all the possible side effects you may feel when taking PEDIAPRED. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:
- indigestion
- increased appetite
- nervousness or restlessness
- trouble sleeping
- weight gain
- loss of muscles
- red face
- heavy sweating
- sore throat
- black or tarry stools
- headache

PEDIAPRED can cause abnormal exam, x-ray, urine, blood pressure and blood test results. Your healthcare professional will do some tests before and during your treatment. The healthcare professional will interpret the results. They will tell you if there are any abnormalities in your tests that might need treatment.
### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Acute kidney failure</strong> (severe kidney problems): urinating less or not at all, swelling in your legs, ankles or feet, feeling tired, feeling confused, nausea, pain or pressure in your chest, loss of appetite</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Behavior and mood changes</strong>: agitation, aggressive behavior, hostility, irritability, increased eating, confusion, hallucinations</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Bone fracture</strong> (broken bone): area around break will be painful and swollen, inability to bear weight or use affected limb</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Carbohydrate intolerance</strong> (inability to digest some carbohydrates due to a lack of some digestive enzymes): diarrhea, bloating, gas</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Cerebral edema</strong> (swelling in the brain): headache, slow heartrate, irritability, weakness, difficulty talking, drowsiness, fainting, vomiting</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Congestive heart failure</strong> (heart does not pump blood as well as it should): shortness of breath, fatigue, weakness, swelling in ankles, legs and feet, cough, lack of appetite, nausea, rapid or irregular heartbeat</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Convulsion</strong>: seizure, spasms, shaking, fits</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Cushing's Syndrome</strong>: rounded &quot;moon&quot; face, fragile skin that bruises easily, severe fatigue, muscle weakness, headache, impaired growth in children</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Decreased adrenal function</strong>: tiredness, weakness, body aches, nausea, vomiting, loss of appetite, low blood pressure, light-headedness, loss of body hair, skin discoloration, weight loss</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Depression</strong> (sad mood that won't go away): difficulty sleeping or sleeping too much, changes in appetite or weight, withdrawal from social situations, thoughts of death or suicide, feelings or worthlessness, guilt, regret, helplessness or hopelessness, reduced libido (sex drive)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Digestive tract ulcers</strong>: heartburn, long-lasting stomach pain, loss of appetite, weight loss, difficulty swallowing, chest pain, nausea</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Electrolyte imbalance</strong>: weakness, drowsiness, muscle pain or cramps, irregular heartbeat</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Eye disorders: blurred vision, loss of vision, sensitivity to light, irritation, pain or redness of the eye or eyelids, increased eye pressure, clouding in the lens of the eye, bulging eyes</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hyperglycemia (high blood sugar): increased thirst, frequent urination, dry skin, headache, blurred vision and fatigue</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hypertensive crisis (a severe increase in blood pressure): chest pain, headache with confusion and blurred vision, nausea, vomiting, shortness of breath, seizures</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity (allergic reaction): fever, skin rash, hives, itching, swelling, shortness of breath, wheezing, itchy, watery eyes</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy (thickened heart muscle): breathlessness, chest pain, irregular heartbeat</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Infection: fever and chills, nausea, vomiting, diarrhea, generally feeling unwell</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Osteonecrosis (tiny breaks in a bone leading to eventual collapse): pain in bones, limited range of motion in a joint or limb</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis (thin, fragile bones): broken bones, pain, back or rib pain that gets worse when standing or walking</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis (inflammation of the pancreas): abdominal pain, fever, rapid pulse, nausea, vomiting</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Skin disorders: acne, excessive hair growth, thinning of skin, rash, bruising, painful red lumps, stretch marks, pain in joints and muscles</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Tendon rupture: snapping or popping of a muscle in an arm or leg, severe pain, bruising, inability to use affected arm or leg</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Tuberculosis (reactivation of lung disease): cough, fever, weight loss</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Tumor Lysis Syndrome (the rapid death of cancer cells due to the treatment): changes in blood test results (uric acid, potassium, phosphorus, calcium), seizures, lack of urination, darkening of urine, irregular heartbeat</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vaginal bleeding changes: increased or decreased menstrual bleeding, spotting, infrequent periods, absence of bleeding</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vertigo (a sense of spinning and dizziness)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Wound complication: a wound that does not heal</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
**Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting ([https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html)) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

**Storage:**

Store at 15 -30°C. Do not refrigerate. Keep bottle tightly closed.

Keep out of reach and sight of children.

**If you want more information about PEDIAPRED:**

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website ([https://www.canada.ca/en/health-canada.html](https://www.canada.ca/en/health-canada.html)); the manufacturer’s website www.sanofi.ca, or by calling 1-800-265-7927.

This leaflet was prepared by sanofi-aventis Canada Inc.

Last Revised December 21, 2020